Alkermes’ narcolepsy drug shows promise in mid-stage trial

(Reuters) -Alkermes’ experimental drug significantly improved wakefulness and reduced excessive sleepiness in patients with a rare sleep disorder in a mid-stage study, it said on Wednesday.

The company was testing the drug, alixorexton, in patients with narcolepsy type 2, a chronic neurological disorder that disrupts the brain’s ability to control sleep and wake cycles.

The drug was generally well-tolerated, with most side effects being mild to moderate, the company said.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Anil D’Silva and Sahal Muhammed)